Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
Date:11/5/2012

SAN DIEGO, Nov. 5, 2012  /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the third quarter and nine months ended September 30, 2012.

Highlights from the third quarter include:

  • Net product revenue for the third quarter of 2012 was $13.9 million, an increase of $2.8 million, or 25%, from $11.1 million for the second quarter of 2012
  • Net product revenue for the nine months ended September 30, 2012, was $33.0 million, which is $27.4 million, or nearly five times, higher than the $5.6 million of net product revenue reported for the same period in 2011
  • The customer base for OFIRMEV increased by 10% during the third quarter as compared to the second quarter of this year, with a total of nearly 3,500 unique customer accounts at September 30, 2012
  • The gross margin on sales of OFIRMEV was 56% for the third quarter of 2012, which represents an improvement over the 48% gross margin reported for the second quarter of 2012
  • As of September 30, 2012, OFIRMEV was on formulary at over 2,000 institutions throughout the U.S.

    • "With strong third quarter sales growth and continued expansion of its user base, we believe that OFIRMEV, used as the foundation of a multimodal analgesic approach, is on track to become a standard of care in acute pain management. An increasing number of physicians and hospitals are choosing OFIRMEV to effectively manage acute pain and to reduce opioid use. OFIRMEV's customer base has nearly doubled over the past year and it is now being used in over 70% of the top 2,000 accounts in the country, when ranked by the quantity of IV analgesic products purchased," said Ted Schroeder, President and C
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
    3. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
    4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    8. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
    (Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
    (Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
    Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
    (Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
    (Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
    (Date:6/19/2013)... study published in the June 19 online edition of ... by researchers from the University of California, San Diego ... that take place when cardiac regeneration occurs in zebrafish ... that various cell lines in the heart are more ... than previously thought. , More importantly, the research reveals ...
    (Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
    (Date:6/19/2013)... -- Nearly 70 percent of Americans are ... than half take two, Mayo Clinic researchers say. ... prescribed, their study found. Twenty percent of patients ... to the findings, published online in the journal ... For audio and video of Dr. Jennifer St. ...
    Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
    ... ... the most widely used resource for consumers looking for a top doctor in their community. ... New York, NY (PRWEB) November 16, 2009 ... many dating sites and search through endless profiles until they find their match. Want to ...
    ... ... of Trendy Socks for Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross ... today its marketplace debut and the launch of “Cool Clothes for Toes,” the first creatively ...
    ... ... has been selected by Goldline Research as one of the leading Laser ... Laser Eye Surgeons of the United States has been published in the ... vision trials, and originator of LASIK in Denver, Colorado, Dr. Jon Dishler ...
    ... Nov. 16 Acknowledging that their results are "not ... International Journal of Andrology nevertheless attempt to link reduced masculine ... exposure to phthalates. The researchers, led by Dr. Shanna ... much publicized, study of phthalate exposure to evaluate the play ...
    ... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... the Company will hold a teleconference and webcast at 8:00 a.m. ... pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial ... , Conference Call and Webcast Information , To ...
    ... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
    Cached Medicine News:Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2
    Made exclusively from LactoSorb® Resorbable Copolymer....
    The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
    ... Stryker Conquest Suture Retrievers ... that pierce through soft ... through the tissue to ... Conquest Retrievers are front ...
    ... excising soft tissue more efficiently than a punch ... edge on the straight scissor helps to maintain ... jaws for more efficient resection.,The curved scissors, available ... perfect tools for ACL stump removal, meniscectomies and ...
    Medicine Products: